atebimetinib — Initial data
Q4 2026
• Q4 2026: Additional preclinical data of atebimetinib in combination with anti-PD-1 in non-small cell lung cancer.Source filing
IMRX biotech catalysts & pipeline
IMMUNEERING CORP · Data as of 2026-09-08
Upcoming catalysts
atebimetinib — Interim data
late-2027
• 2H 2026 : Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in non-small cell lung cancer, with a preliminary data readout expected in late-2027.Source filing
atebimetinib — Topline data
Mid-2028
• Mid-2028: Topline data readout from the MAPKeeper 301 trial.Source filing